{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:23:03Z","timestamp":1777998183114,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-S114008"],"award-info":[{"award-number":["KMU-S114008"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euros.2025.12.005","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T13:06:49Z","timestamp":1767100009000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0664-0637","authenticated-orcid":false,"given":"Shao-Yuan","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Pin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Lung","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang-Shun","family":"Chueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Chih","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsuan-Yu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-3957","authenticated-orcid":false,"given":"Chung-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.12.005_b0005","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): prostate cancer. Plymouth Meeting, PA: NCCN; 2025."},{"key":"10.1016\/j.euros.2025.12.005_b0010","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2025.12.005_b0015","article-title":"The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: a network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.euros.2025.12.005_b0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.005_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.005_b0030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.005_b0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.005_b0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.005_b0045","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/jjco\/hyab071","article-title":"Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer in Japan","volume":"51","author":"Okumura","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.005_b0050","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","article-title":"An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"van Andel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2025.12.005_b0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euros.2025.12.005_b0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mlr.0000254515.63841.81","article-title":"Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients","volume":"45","author":"Pickard","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.euros.2025.12.005_b0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40258-019-00467-6","article-title":"An updated systematic review of studies mapping (or cross-walking) measures of health-related quality of life to generic preference-based measures to generate utility values","volume":"17","author":"Mukuria","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.euros.2025.12.005_b0070","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.eururo.2014.08.075","article-title":"Defining a standard set of patient-centered outcomes for men with localized prostate cancer","volume":"67","author":"Martin","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.005_b0075","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00195.x","article-title":"Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients","volume":"10","author":"Wu","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.euros.2025.12.005_b0080","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","article-title":"The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration","volume":"33","author":"Petrou","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euros.2025.12.005_b0085","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/001316447003000308","article-title":"Determining sample size for research activities","volume":"30","author":"Krejcie","year":"1970","journal-title":"Educ Psychol Meas"},{"key":"10.1016\/j.euros.2025.12.005_b0090","unstructured":"EuroQol Group. EQ-5D. Available versions. https:\/\/euroqol.org\/register\/obtain-eq-5d\/available-versions\/."},{"key":"10.1016\/j.euros.2025.12.005_b0095","unstructured":"EORTC Quality of Life Group. Questionnaires. https:\/\/qol.eortc.org\/questionnaires\/."},{"key":"10.1016\/j.euros.2025.12.005_b0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1477-7525-10-96","article-title":"Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients","volume":"10","author":"Chang","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euros.2025.12.005_b0105","series-title":"Measuring prostate cancer quality of life: psychometric properties of the EORTC-C30 and EORTC-PR25","author":"Chang","year":"2008"},{"key":"10.1016\/j.euros.2025.12.005_b0110","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s10198-020-01220-w","article-title":"Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas","volume":"21","author":"Xu","year":"2020","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.euros.2025.12.005_b0115","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12955-020-01611-w","article-title":"Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer","volume":"18","author":"Hagiwara","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euros.2025.12.005_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209344","article-title":"Valuation of the EQ-5D-5L in Taiwan","volume":"13","author":"Lin","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.euros.2025.12.005_b0125","series-title":"The EORTC QLQ-C30 scoring manual (3rd edition)","author":"Fayers","year":"2001"},{"key":"10.1016\/j.euros.2025.12.005_b0130","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11764-023-01509-8","article-title":"Health-related quality of life among prostate cancer survivors with metastatic disease and non-metastatic disease and men without a cancer history in the USA","volume":"19","author":"Zheng","year":"2025","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.euros.2025.12.005_b0135","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/PPA.S461027","article-title":"Exploring the hidden struggles: a qualitative insight into urinary incontinence among prostate cancer survivors post-surgery","volume":"18","author":"Sun","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.euros.2025.12.005_b0140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5152\/ArcHealthSciRes.2024.23073","article-title":"Effects of androgen deprivation therapy duration on health-related quality of life, physical activity, anxiety and depression levels in patients with intermediate- and high-risk prostate cancer","volume":"11","author":"Feyzio\u011flu","year":"2024","journal-title":"Arch Health Sci Res"},{"key":"10.1016\/j.euros.2025.12.005_b0145","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0090-4295(02)01552-2","article-title":"Impact of prostate cancer screening on health-related quality of life in at-risk families","volume":"59","author":"Cormier","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.euros.2025.12.005_b0150","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1023\/A:1008938326604","article-title":"The use of the tobit model for analyzing measures of health status","volume":"9","author":"Austin","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1016\/j.euros.2025.12.005_b0155","first-page":"867","article-title":"Application of adjusted limited dependent variable mixed model in the mapping of pharmacoeconomic health utility scale","volume":"33","author":"Wan","year":"2022","journal-title":"China Pharmacy"},{"key":"10.1016\/j.euros.2025.12.005_b0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41256-024-00393-8","article-title":"Effects of population aging on quality of life and disease burden: a population-based study","volume":"10","author":"Xi","year":"2025","journal-title":"Glob Health Res Policy"},{"key":"10.1016\/j.euros.2025.12.005_b0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5534\/wjmh.230042","article-title":"Health-related quality of life assessment in prostate cancer patient undergoing androgen deprivation therapy: real-world experience in the READT study","volume":"42","author":"Lim","year":"2024","journal-title":"World J Mens Health"},{"key":"10.1016\/j.euros.2025.12.005_b0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12894-022-00979-9","article-title":"Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan","volume":"22","author":"Leith","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.euros.2025.12.005_b0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/10781552231221110","article-title":"Management and health-related quality of life among patients with prostate cancer in a Kenyan tertiary health facility","volume":"31","author":"Karaihira","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.euros.2025.12.005_b0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.21037\/tau.2016.08.12","article-title":"Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment","volume":"6","author":"Chambers","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euros.2025.12.005_b0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","article-title":"A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures","volume":"11","author":"Brazier","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.euros.2025.12.005_b0190","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/JTO.0b013e3181f77a6a","article-title":"Derivation of utility values from European organization for research and treatment of cancer quality of life-core 30 questionnaire values in lung cancer","volume":"5","author":"Jang","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.euros.2025.12.005_b0195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10198-010-0233-7","article-title":"Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences","volume":"11","author":"Crott","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.euros.2025.12.005_b0200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-12-35","article-title":"Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma","volume":"12","author":"Proskorovsky","year":"2014","journal-title":"Health Qual Life Outcomes"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832502484X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832502484X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:50:20Z","timestamp":1773949820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266616832502484X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"alternative-id":["S266616832502484X"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.005","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}